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1. INTRODUCTION  
HIV infection/AIDS is a global pandemic with cases reported from virtually every 
country. The current estimate of cases among adults is estimated to be around 37 million. 
Two thirds of them live in Sub Saharan Africa and 50% are women. The prevalence 
ranges from 0.6% to 8% in different parts of the world.1 
Gastroenterological manifestations are quite common in advanced HIV infection/ AIDS 
and are some times initial manifestations or AIDS defining illness. Liver involvement is 
unique since it can be because of direct involvement, opportunistic infections (OI ) with r 
co-infection of one or more hepatotrophic viruses, or because of toxicity due to retroviral 
drugs.2 
HEPATIC MANIFESTATION OF HIV/AIDS 
Presence of liver disease is a frequent finding in AIDS. Hepatomegaly may be detected 
on examination in most patients. Hepatomegaly is usually associated with one or more 
liver chemistry test abnormalities, although significant jaundice due to parenchymal 
disease is uncommon. As with other organ systems, the spectrum of hepatic infections in 
patients with HIV evolves as immunocompromise advances. Clinical manifestations of 
hepatobiliary disease can vary from no symptoms to liver failure. 
 Hepatobiliary disease can be broadly classified into either hepatic parenchymal 
abnormalities, biliary abnormalities, or a combination of the two. Currently, 
parenchymal abnormalities are most often related to viral hepatitis and drug-induced 
disease; however, neoplasms, in particular non-Hodgkin's lymphoma, and OIs are not 
infrequent 
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Drug-induced liver injury has emerged as the most prevalent cause of liver test 
abnormalities and is related to the increasing array of antiretroviral medications. Use of 
prescription or nonprescription drugs as well as herbal remedies should also be 
considered a cause of abnormal liver test results in the HIV-infected patient. Before 
HAART, drug hepatotoxicity was most commonly due to sulfonamides, and the 
increased frequency of adverse reactions to these medication is well recognized in AIDS.  
 Well established syndromes characterized by marked hepatomegaly, steatosis, lactic 
acidosis, and liver failure has been increasingly recognized.Hepatic steatosis is usually 
evident on imaging of the liver. Although reversal has occurred in some patients 
following drug withdrawal, most patients have worsening disease and death. Liver 
transplantation is curative. 
 The incidence of drug induced hepatotoxicity, its mechanisms, evaluation, management, 
analyses of various studies on the risk factors and prognosis are described in detail in 
literature review. Other causes of liver dysfunctions are reviewed below and should be 
kept in mind before evaluating these patients.2 
INFECTIONS 
Mycobacterium avium intercellulare complex (MAC)  is consistently the most frequent 
specific hepatic finding in AIDS, documented in up to 46% of patients in late-stage HIV 
disease. The pathologic hallmark of the infection is the presence of poorly formed 
granulomas containing acid-fast bacilli within foamy histiocytes. Organisms may be 
observed in the absence of granulomas and can be cultured from liver biopsy in the 
absence of infected histiocytes 
 
 7
 
Mycobacterium. tuberculosis, in contrast to MAC, may occur before HIV-infected 
patients are profoundly immunocompromised. Extrapulmonary tuberculosis is common 
in patients with HIV infection, especially in patients with prior OIs and those whose risk 
behavior is injection drug use. Hepatic disease as part of miliary tuberculosis has been 
noted. Rarer manifestations include tuberculous abscesses and bile duct tuberculomas. 
The diagnosis of hepatic tuberculosis is made by culture of the organism from liver 
tissue obtained by percutaneous or laparoscopic biopsy. PCR may be helpful.  
CMV is the most frequent infectious pathogen in AIDS, and the liver is involved in 5% to 
25% of liver biopsies. However, its discovery in the liver antemortem is extremely 
unusual. Typical viral inclusions are usually identified in Kupffer cells . 
Clinical manifestations and histologic features of viral hepatitis from HBV, HCV, or 
hepatitis D virus are altered in the presence of HIV coinfection but in remarkably 
different ways for each virus. 
Clinical and autopsy studies in AIDS patients have reported up to a 90% seroprevalence 
of hepatitis B markers indicating past or present infection. 
 Concurrent HIV and HBV infections lead to alterations of HBV antigen-antibody 
display, viral replication, and clinical consequences. Several reports have described 
reappearance of hepatitis B surface antigen (HBsAg) in HIV-infected patients previously 
thought to be immune to hepatitis B virus as indicated by the presence of anti-HBs.5  
Recurrence of HBsAg may arise from either reinfection or reactivation with advanced 
immunodeficiency. In addition, there is an accelerated loss of naturally acquired anti-
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HBs even in those patients who remain HBsAg negative. With loss or reduction in 
immunity to HBV, there is an increased prevalence of hepatitis B e antigen expression, 
elevated mean levels of DNA polymerase, and increased titers of anti–hepatitis B core 
antigen.6 
Acquisition of the chronic carrier state is also much more likely in the HIV-infected 
patient, especially if infection occurs when immunodeficiency is more advanced. Thus, a 
larger proportion of patients with HIV and hepatitis B infections have a chronic carrier 
state, with highly infectious serum and body fluids, compared with those who are HIV 
negative 
Although HIV infection leads to more prevalent chronic HBV carriage, it appears to 
attenuate the severity of biochemical and histologic liver disease in most, but not all1 
patients. In one study, the mean alanine aminotransferase (ALT) level correlated with 
CD4 lymphocyte count. The mechanism for reduced hepatitis B virus–related liver injury 
following HIV infection is not certain but has been attributed to a diminution in 
lymphocyte-mediated hepatocellular injury as a result of HIV effects on lymphocytes. In 
those patients without serologic evidence of past or present hepatitis B virus and HIV 
infection, vaccination appears to be ineffective, regardless of the stage of 
immunocompromise.   
Sometimes the institution of HAART in a chronic carrier of hepatitis B virus can have 
catastrophic consequences. Patients may develop an acute flare of hepatitis that can be 
severe leading to fulminant hepatic failure. However, the proportion of coinfected 
patients who develop an acute hepatitis B flare following use of HAART is unknown. It 
is believed that reconstitution of immune function with HAART leads to production of 
antibody that is directed to infected hepatocytes as in the normal host. Inclusion of 
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lamivudine, which has potent antiviral effects on hepatitis B virus, in the HAART 
regimen may reduce the likelihood of acute hepatitis B.6  
The consequences of HIV infection on delta hepatitis appear similar to those of HBV, 
although far fewer patients have been studied.  
The prevalence of HCV in those with HIV infection depends on the risk group evaluated 
and the assay used. Prevalence is highest in injection drug users (52% to 89%)7,8 and 
hemophiliac patients with HIV, whereas in military populations and non–drug users, the 
prevalence is much lower, ranging from 1% to 11%. Assaying antibodies to hepatitis C 
virus alone, rather than hepatitis C virus RNA, may underestimate the true prevalence, 
because loss of antibody may occur with progression of immunodeficiency.5, 6  
Unlike hepatitis B virus, the clinical course of hepatitis C virus appears to worsen as 
HIV-related immunocompromise advances. This has been best documented in HIV-
infected hemophiliac patients. Studies in large cohorts of hemophiliac patients have 
demonstrated dramatic increases in hepatitis C virus RNA levels with progressive HIV 
disease, associated with aspartate aminotransferase (AST) elevations and hepatomegaly. 
Co infected patients also have a higher rate of active cirrhosis on biopsy and an 
accelerated course to clinical cirrhosis and liver failure. The mechanism for this more 
rapid disease course is unknown but has been similarly recognized in other 
immunocompromised patients. Because patients with late-stage HIV often have multiple 
life-threatening infections, HCV alone is not an independent determinant of mortality. 
However, as HIV-infected patients are living longer owing to HAART, hepatitis C 
virus–induced liver disease and its consequences (e.g., hepatocellular cancer) are 
assuming more clinical relevance. Like hepatitis B, hepatitis C virus does not cause 
progression of HIV disease. 7 
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The effect of HAART on hepatitis C viral dynamics and liver injury is variable. Some 
studies have found attenuation of disease, whereas others had documented exacerbations 
reflected by increases in serum transaminases. Hepatitis C viral load has also been 
variably affected. 8 
The role of interferon therapy for HIV/HCV coinfected patients remains unsettled. α-
Interferon is less effective for treating hepatitis C virus liver disease in coinfected 
patients . More recently, combination therapy of Peg-interferon and ribavirin has shown 
promise. 10 
Fungal infections of the liver are not unusual when immunocompromise is advanced. 
Histoplasmosis of the liver may be seen in patients with disseminated fungal disease, 
predominantly but not exclusively in regions of high prevalence of the organism. 
Biopsies of the liver may also show caseating granulomas containing fungal organisms. 
Culture of hepatic tissue, blood, or bone marrow can confirm the diagnosis, but several 
weeks may be required for the organism to grow in culture.  
Pulmonary disease is seen in most patients at diagnosis.Cryptococcus may infect the 
liver in the setting of disseminated infection. Typically the organism is found in the 
sinusoids and is associated with a poor inflammatory response. Similarly, 
coccidioidomycosis can involve the liver as part of a systemic infection, especially in 
endemic regions. The organisms appear as spherules within a fibrosing 
granulomata.Candida infection of the liver is rare, in contrast to its high prevalence in 
mucosal sites. Hepatic microabscesses or macroabscesses are most likely to occur if the 
patient is neutropenic, especially following chemotherapy for non-Hodgkin's lymphoma. 
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Kaposi's sarcoma, which is caused by infection with human herpesvirus 8 (HHV-8) has a 
predilection for periportal regions of the liver and is seen in 10% to 15% of liver 
biopsies.  
Tumor nodules appear grossly as violaceous or hemorrhagic masses within hepatic 
parenchyma. Microscopically, the characteristic spindle cells and vascular slits of 
Kaposi's sarcoma usually directly abut normal-appearing liver tissue.  
Hepatic involvement by non-Hodgkin's lymphoma may be the index manifestation of 
AIDS in homosexual men and may be the primary site of the neoplasm. The lesions are 
usually focal and may be large. In addition, Hodgkin's disease in the AIDS patient tends 
to be more aggressive histologically and clinically, spreading rapidly to extranodal sites, 
making liver involvement more likely.  
Isolated cases of P. carinii pneumonia (PCP) hepatitis have been described and are 
attributable to the use of inhaled pentamidine, which fails to protect extrapulmonic sites 
from PCP. In addition to PCP, the liver may be the site of infection by the protozoa 
Cryptosporidium, Microsporidium, or Dicrocoelium dentriticum or by other multicellular 
organisms. 
Bacillary peliosis hepatis, may be caused by either Bartonella henselae or Bartonella 
Quintana. 
The significance of a number of the nonspecific findings in the liver are uncertain. In 
particular, granulomas in the absence of fungal or mycobacterial organisms are common, 
often prompting concern for tuberculosis. Microvesicular and macrovesicular steatosis is 
one of the most common nonspecific findings, possibly owing to malnutrition, because 
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the findings are similar to those seen in patients with kwashiorkor. Massive steatosis has 
also been observed from antiretroviral drug use (lipodystrophy syndrome). 
Biliary tract involvement in AIDS may result in marked liver test abnormalities and right 
upper quadrant symptoms; jaundice is unusual. A syndrome resembling sclerosing 
cholangitis with papillary stenosis is well recognized and has been termed AIDS 
cholangiopathy. Patients characteristically develop significant upper abdominal pain in 
association with marked elevation of alkaline phosphatase, and minimal elevations of 
bilirubin, AST, and ALT.  
Ductular changes may consist of either papillary stenosis alone, sclerosing cholangitis–
like lesions alone, a combination of the two, or long extrahepatic strictures. Most series 
have found papillary stenosis with intrahepatic disease as the most common findings. 
Ultrasonography or CT detects ductular abnormalities in 77% of those with 
cholangiographically proven disease, implying that a negative imaging study does not 
definitively exclude the diagnosis. The etiology in most cases is infectious because 
Cryptosporidium, CMV, or Microsporidium may be found in bile, duodenal, or biliary 
epithelium. For patients with predominantly papillary stenosis, sphincterotomy results in 
a symptomatic improvement in most patients; alkaline phosphatase may continue to rise, 
however, probably reflecting progression of associated intrahepatic disease. 
 Other less common causes of biliary tract disease in AIDS include primary bile duct 
lymphoma, epithelial angiomatosis, lymphomatous nodal obstruction, Kaposi's sarcoma, 
and biloma. In addition, chronic pancreatitis or choledocholithiasis may lead to biliary 
obstruction, although their incidence is not clearly increased in HIV infection.3,4 
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EVALUATION 
The initial decision in evaluating the AIDS patient with jaundice, hepatomegaly, or both, 
is to determine whether the findings are due to intrahepatic or extrahepatic disease. 
Simultaneous disease in both sites must also be considered. A history of mild jaundice, 
often in association with fever and constitutional symptoms, is more consistent with 
intrahepatic disease, whereas symptoms of deep jaundice associated with pain of 
relatively acute onset suggest extrahepatic disease. Careful review of medications, both 
prescription and nonprescription, is essential. 
Because the clinical history and the finding of symptomatic hepatomegaly are 
nonspecific, further evaluation is always necessary. Elevations of ALT or AST or both, 
are common, but neither the pattern nor the extent of elevation of these tests appears to 
correlate with specific findings in the liver. Significant elevation of the transaminases 
favors a drug-induced or viral cause. In contrast, marked elevation of alkaline 
phosphatase correlates statistically with the presence of MAC infection in the liver in 
AIDS when extrahepatic obstruction is absent. CT scan and ultrasonography should be 
employed early because they are especially useful in identifying ductal dilation, 
gallbladder pathology, and focal hepatic lesions.  
The indications for liver biopsy for the patient in whom intrahepatic disease is suspected 
are not well defined. Biopsy is appropriate when symptomatic, treatable disease of the 
liver is suspected and when a specific diagnosis of hepatic disease is needed.  
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An extrahepatic cause for jaundice is suggested on CT or ultrasonography by the 
presence of dilated ducts or other biliary and/or pancreatic abnormalities. Once 
extrahepatic obstruction is recognized, the possibility of papillary stenosis associated 
with AIDS cholangiopathy must be considered as well as the possibility of 
choledocholithiasis or other disorders, depending on the imaging studies. Further 
evaluation, when indicated, may include endoscopic retrograde 
cholangiopancreatography (ERCP) if CT or ultrasonography demonstrates extrahepatic 
biliary ductal dilation. Ampullary and duodenal biopsy specimens or bile and/or biliary 
cytology (with appropriate staining) collected during ERCP can be examined for the 
presence of viruses, protozoa, or neoplastic cells. 2,3,4 
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Table 1.1 : Major cause of liver injury in HIV infection 
Drugs 
NRTI, NNRTI, PI 
Anti microbials 
Antituberculosis , INH, rifampicin 
Macrolides : clarithromycin, azithromycin 
Antifungal : KTZ, itraconazole, fluconazole 
Anti pneumocystitis carini drugs : TMP-SMX, dapsone 
Infections  
Viral hepatitis 
HAV, HBV, HCV, CMV, HSV, EBV 
Mycobacteria,Mycobacterium avium, M tuberculosis 
Fungal  
Cryptococcus, histoplasma, coccidioides, candidia 
Protozoa 
Pneumocystitis, toxoplasma,microsporidia, cryptosporidium 
 
Biliary infections 
HIV cholangiopathy 
Acalculouscholecystitis 
Neoplasm and vascular lesions 
Kaposi sarcoma 
Lymphoma 
Peliosis hepatitis 
Steatosis and lipodystrophy 
HCV co-infection 
Drugs associated 
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2. REVIEW OF LITRETURE 
Since its introduction over 10 years ago, highly active antiretroviral therapy (HAART) 
has dramatically changed the course of human immunodeficiency virus (HIV) infection 
by decreasing morbidity and mortality as a result of opportunistic infections.   However, 
HIV-infected patients are now experiencing a wide array of adverse events attributed to 
the drugs themselves.  Liver toxicity is an important example because it carries its own 
morbidity and mortality.  Perhaps more importantly, it often leads to HAART 
discontinuation 
HAART INDUCED LIVER DISEASE 
Highly active antiretroviral therapy (HAART) has decreased the morbidity and mortality 
derived from classical opportunistic infections. As a counterweight to this positive 
impact, antiretroviral therapy (ART) carries along undesirable effects, which challenge 
the management of HIV-infected patients to a great extent. Among these, liver toxicity 
deserves a special attention since it often leads to HAART discontinuation; particularly 
in hepatitis C (HCV) and/or hepatitis B (HBV) co-infected patients. The mechanisms 
involved in HAART-derived liver toxicity are not well understood, which makes its 
management more difficult 
One of the toxicities linked to the use of antiretrovirals is the elevation of transaminases. 
Liver toxicity is a cause of morbidity, mortality, and treatment discontinuation in HIV-
infected patients. While several antiretrovirals have been reported to cause fatal acute 
hepatitis, they most often cause asymptomatic elevations of transaminases 
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 Possible pathogenic mechanisms involved in hepatotoxicity are multiple, including 
direct drug toxicity, immune reconstitution in the presence of HCV and/or HBV co-
infections, hypersensitivity reactions with liver involvement, and mitochondrial toxicity. 
Other pathogenic pathways may be involved, such as insulin resistance caused by several 
antiretrovirals, which may contribute to the development of steatohepatitis. The 
management of liver toxicity is based mainly on its clinical impact, severity and 
pathogenic mechanism. 
CLINICAL IMPACT  
With the widespread use of HAART and the availability of more drugs, some of them 
perhaps more hepatotoxic, HAART-linked hepatotoxicity has been made evident over 
the past few years. Liver toxicity generates medical visits, work-up exams, and frequent 
hospital admissions, all of which increase expenses. In addition, hepatotoxicity hampers 
the maintenance of HIV suppression over time. 
In a recent American study, which evaluated the causes of death of HIV-infected 
individuals, discontinuation of ART due to hepatotoxicity increased from 6% in 1996 to 
31.8% in 1998-1999 among those mortalities . More recently, Kramer and colleagues 
have highlighted the increase in the number of cases of fulminant liver failure in 
HIV/HCV-coinfected individuals during the HAART era, even after excluding patients 
with advanced liver disease and adjusting by alcohol intake. 
The severity of liver toxicity ranges from the absence of symptoms to liver 
decompensation; and the outcome, from spontaneous resolution to liver failure and 
death. Although in a study severe hepatotoxicity with acute hepatic necrosis was present 
in 2% of HIV+ patients dying due to hepatitis or other liver diseases, mainly among 
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those with prior liver disease, most cases of liver toxicity is mild-to-moderate and 
asymptomatic .  
Drug liver toxicity has impacted on the recommendations for antiretroviral therapy in 
certain scenarios. Thus, the use of nevirapine (NVP) has been recommended to be 
avoided as part of post-exposure prophylaxis regimens. The reason for that was the 
occurrence of fulminant hepatitis in two cases and severe liver toxicity in 12 other 
healthy subjects who received a NVP-including HAART regimen after HIV exposure. 
However, NVP seems to be safe when administered to mother and child as a single dose 
for prevention of mother-to-child HIV transmission . 3,4 
DEFINITION OF LIVER INJURY 
The clinician thinks of liver damage when abnormalities in the liver tests are seen. There 
is a broad variability among studies in the criteria to categorize the severity of 
hepatotoxicity. the most accepted one, the AIDS Clinical Trials Group scale of liver 
toxicity . 
 According to it, patients with transaminases within normal limits at baseline are 
considered to develop hepatotoxicity when ALT and/or AST rise above the upper limits 
of normal (ULN). Severe hepatic injury (the primary study outcome) is defined as grade 
3 or 4 change in AST and/or ALT levels during antiretroviral treatment. If AST and ALT 
grades were discordant, the highest should be used for classification purposes. 
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DEFINITIONS OF HAART-ASSOCIATED HEPATOTOXICITY: 15 
The AIDS Clinical Trials Group  currently uses the following toxicity grading scale: 
Patients with normal pretreatment ALT/AST:  
Grade 0 hepatotoxicity          <1.25 times the ULN (upper limit of normal) 
Grade 1 hepatotoxicity         1.25 to 2.5 times the ULN 
Grade 2 hepatotoxicity         2.5 to 5 times the ULN 
Grade 3 hepatotoxicity         5.1 to 10 times the ULN 
Grade 4 hepatotoxicity          >10 times the ULN 
There is a separate grading scale for the HAART-associated cholestasis: 
Grade 0 cholestasis          <1.1 times the ULN 
Grade 1 cholestasis         1.1 to 1.5 times the ULN 
Grade 2 cholestasis         1.6 to 2.9 times the ULN 
Grade 3 cholestasis         3 to 5 times the ULN 
Grade 4 cholestasis          >5 times the ULN 
For patients with elevated pretreatment ALT/AST, changes are compared to baseline 
rather than upper limit of normal.  Grades 0 and 1 are identical, but grade 2 is associated 
with ALT/AST 2.6 to 3.5 times baseline, grade 3 3.6 to 5 times baseline, and grade 4 
greater than 5 times baseline. 15 
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Severe hepatotoxocity is defined as grade 3 or 4 change in transaminase levels, while 
severe cholestasis, analyzed independent of transaminase levels, is defined as grade 3 or 
4 change in total bilirubin. 
Many drugs increase γ-glutamyltranspeptidase (GGT) levels. This is often misinterpreted 
as a marker of liver damage, but the isolated elevation of this enzyme actually reflects 
enzyme induction. Only when associated with a proportional increase in alkaline 
phosphatase levels should it be considered as a cholestatic lesion. Bilirubin should not be 
considered itself as indicator of liver toxicicity it can be elevated due to a variety of 
reasons, such as hemolysis, fasting and certain drugs (e.g. indinavir and atazanavir). In 
addition to HAART-derived hepatotoxicity, some other conditions or drugs used in HIV 
infection, can cause elevations in the levels of liver enzymes and should be ruled out. 
  
INCIDENCE AND RISK FACTORS 
The reported incidence of severe liver toxicity after initiating HAART ranges from 2 to 
18% . Differences in the study populations, as well as in the methods used probably 
account for the wide range. In Tables 1 and 2, which summarize the main trials assessing 
liver toxicity in patients taking antiretroviral therapy, the risk factors are recorded. 
Hepatitis B and C co-infections 14 
Liver toxicity, especially severe toxicity (grades 3 and 4), is clearly more frequent in 
HCV and/or HBV co-infected individuals treated with HAART . In one study, a higher 
risk of hepatotoxicity was found in patients carrying HCV genotype 3 (HCV-3) 
compared to other genotypes . The clinical implications of this finding are 2-fold. On one 
hand, the presence of HCV-3 may impact on the selection of HAART regimen, choosing 
those with less potential for hepatotoxicity. On the other hand, since genotype 3 shows a 
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higher response to interferon (IFN) and ribavirin (RBV), anti-HCV treatment should be 
given if no major contraindication is present. 
ANTIRETROVIRALS  
The results of the studies that have evaluated the risk for liver toxicity associated with 
the use of particular antiretroviral drugs or families are conflicting. The unbalanced and 
often insufficient representation of some antiretrovirals in these series, make it difficult 
to determine with accuracy the role of each particular drug in the development of liver 
toxicity. In addition, the use of several antiretrovirals combined makes it difficult to 
ascribe the elevation of transaminases to single drugs. 16 
Protease inhibitors 
The phenomenon of hepatotoxicity became more evident after the introduction of ART 
of high activity, which initially included invariably a protease inhibitor (PI). However, 
none of the studies has been able to prove the higher potential for liver toxicity of this 
particular family of drugs. Among the PI, in some studies full-dose ritonavir (RTV) has 
been found to be more hepatotoxic .In certain cases, RTV has caused fatal acute 
hepatitis. Several cases of liver toxicity associated with the use of indinavir (IDV) and 
saquinavir (SQV) have also been reported . Nelfinavir was found to be less hepatotoxic 
than the other PI anlyzed . 
The use of two PI, which often includes RTV at low doses as a booster for the second PI, 
does not seem to increase the risk of toxicity for the liver. The incidence of liver toxicity 
with lopinavir (LPV), which is given with low doses of RTV (200mg/day) is low . 
Atazanavir, marketed more recently, seems also to have a good safety profile regarding 
the liver, even if used with low-dose RTV . Tipranavir, recently approved, appears to be 
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more hepatotoxic, most probably because it is given with higher doses of RTV 
(400mg/day). 
Nucleoside analogues reverse transcriptase inhibitors (NRTI) 
Some authors have found a lower incidence of hepatotoxicity with lamivudine (3TC) and 
tenofovir . However, the majority of the NRTI can induce mitochondrial damage, and, 
therefore, have a potential for the development of liver injury, as it will be explained 
below . Cases of hepatic failure have been reported in patients taking zidovudine, but 
didanosine and stavudine have been most often involved in severe hepatotoxicity . 
Abacavir (ABC) and tenofovir (TDF), with low potential for mitochondrial damage, 
seem to have a safer profile regarding the liver. In patients with chronic hepatitis B, the 
removal of 3TC may be accompanied by a flare of HBV replication, translated into an 
increase in transaminases. 
Non-nucleoside analogues reverse transcriptase inhibitors 
The risk of liver toxicity associated with the non-nucleoside analogues reverse 
transcriptase inhibitors (NNRTI) is variable and involves several aspects and 
mechanisms. Several cases of severe liver toxicity, some of them fatal, in subjects 
receiving NVP as part of a post-exposure prophylaxis regimen. Likewise, in a trial 
assessing the NRTI emtricitabine (FTC), a higher incidence of hepatotoxicity was 
observed among patients taking NVP. Of interest, in both series, the post-exposure 
prophylaxis and the FTC trial, hepatotoxicity developed early into treatment, and 
predominated among black women in the FTC study. These data suggest a 
hypersensitivity reaction causing the liver abnormalities. However, in other reports, the 
hepatotoxicity of NVP-containing regimens had a later onset (beyond the 4th month), 
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with an increase in the cumulative incidence over time . Therefore, it looks like there is a 
second mechanism through which NVP causes liver toxicity, much more common than 
the hypersensitivity syndrome. 
Several retrospective studies have evaluated the development of hepatotoxicity linked to 
the use of NNRTI. This is especially true in populations with a low prevalence of chronic 
HCV infection [43]. While some authors have found a higher risk of liver toxicity for 
NVP compared to efavirenz (EFZ), others have failed to do so . More recently, in a 
randomized clinical trial comparing NVP twice a day, NVP once a day and EFZ, higher 
incidences of severe hepatotoxicity were seen in the NVP groups (13.8% once a day and 
7.2% twice a day) compared to the EFZ arm . However, only the differences between the 
once a day NVP arm and the EFZ arm were statistically significant. 
Taken together, all these data suggest that NNRTI have a greater risk to induce 
immunoallergic reactions involving the liver soon after initiation of therapy. With 
prolonged therapy, especially in HBV and/or HCV co-infected subjects, NNRTI have a 
trend to cause a slight increase in the cumulative incidence of hepatotoxicity, which may 
spontaneously abate over time. Only in rare occasions is liver toxicity serious. In 
particular, morbidity and mortality linked to the use of NVP has not been proven to be 
superior to those of other antiretrovirals.14,15,16 
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Table 2.1 :  Liver toxicity of commonly used anti- HIV medications 
Dug type Drug name Pattern of injury Comments 
Protease inhibitor Indinavir 
Saquinavir 
Nelfinavir 
Ritonivir 
Hepatocellular, 
distinct histologic 
pattern including 
hepatocyte 
ballooning,Kuppfer 
cell activation, 
pericellular zone 3 
fibrosis 
< 10% of patients 
have transaminases 
> 5 ULN Ritonavir 
inhibits P 450 
NRTI ddC 
d4T 
ddl 
AZT 
Microvesicular 
steatosis 
Mitochondrial 
toxicity manifexting 
as lactic asidosis 
NNRTI Nevirapine 
Efavirenz 
Hepatocellular NVP associated 
with grade 4 
toxicity; FDA alert 
 
 
Other factors  
Heavy alcohol intake has also been identified as a risk factor for severe hepatotoxicity in 
patients taking antiretrovirals . Several authors have identified other risk factors for the 
development of HAART-derived liver toxicity, such as the prior presence of 
transaminase elevation, older age , female sex, prior monotherapy , first antiretroviral 
treatment , lack of response to HAART (only observed at 12 months), and an increase in 
the CD4 count after HAART initiation . An association between advanced degrees of 
liver fibrosis and liver toxicity secondary to NNRTI has been recently reported.17 
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Table 2.2 : Common causes and risk factors 
Drugs 
Obestity 
Coinfection with hepatitis viruses 
Advanced disease 
Malignancy 
Organ failure (liver) 
Cardiovascular disease 
 
MECHANISMS OF LIVER TOXICITY 
Despite the numerous published studies on antiretrovirals and hepatotoxicity, many 
unanswered questions still remain, in particular those related to the mechanisms 
involved. The possible mechanisms involved in the development of hepatotoxicity 
associated with the use of antiretrovirals are summarized in Fig. 1. It is probable that 
multiple pathogenic pathways simultaneously concur in some patients, being difficult to 
identify the exact mechanisms involved in the development of hepatotoxicity. 
Table 2.3 : Mechanisms of hepatotoxicity 
Direct toxicity 
Hypersensitivity reaction 
Mitochondrial toxicity 
Metabolic abnormalities 
Immune reconstitution syndrome in HBV/HCV co-infection 
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Direct toxicity 
Antiretrovirals, as any other drug, can induce direct toxicity in the liver. Drugs 
metabolized in the liver through the cytocrom pathways may cause liver toxicity when 
there are polymorphisms in the enzymes . Since many of the antiretrovirals are 
metabolized in the liver through the cytocrome pathways, idiosyncratic polymorphisms 
of the enzymatic complexes might lead to significant heterogeneity in drug metabolism, 
predisposing to the development of hepatotoxicity in certain individuals. Some drugs 
may potentiate the activation of death receptors and/or intracellular stress pathways.  
Hepatocytes promote mechanisms of cytoprotection against the oxidative stress caused 
by drug metabolism. Heat-shock proteins, induced by various forms of stress including 
drugs, may exert cytoprotective functions helping to tolerate potentially damaging 
toxicants . An increase in heat-shock proteins in individuals with polymorphisms may 
help the liver adapt to and minimize drug toxicity. Anti-oxidation stress mechanisms 
might explain the spontaneous normalization in the levels of transaminases despite 
maintenance of HAART, as it occurs with INH. Although still early in its development,  
pharmacogenomics is a new approach, which may be very valuable to predict the risk for 
hepatotoxicity in each individual after initiation of ART . 
Hypersensitivity reactions 
Hypersensitivity reactions are idiosyncratic reactions of the host, not related to the dose 
of the drug. Sulphas are prototypical drugs inducing these immune-mediated reactions 
involving the liver. They usually become apparent within the first 4-6 weeks of 
treatment.  
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In patients taking NVP, the incidence of symptomatic events involving the liver has been 
reported to be of 4.9%. In some occasions  fatal outcomes were linked to the use of NVP 
in women with CD4 counts >250cells/mm within 6 weeks after initiation of treatment, 
due to hypersensitivity reactions. According to a recent analysis, a low body mass index 
is an independent risk factor for this type of events.  
Immune mediated drug reactions seem to involve the generation of neoantigens formed 
by the reaction of liver proteins with reactive drug metabolites . Assays examining in 
vitro activation of peripheral blood mononuclear cells against a drug or its metabolites 
are currently under research. These assays are a promising approach to identify 
susceptible individuals . On the other hand, individuals with the HLA-DRB1*0101 
marker, especially if they have <25% CD4 cells, have been shown to be at greater risk of 
developing NVP-induced hypersensitivity reactions. 
Hypersensitivity reactions have been reported relatively often with NVP and abacavir 
(ABC), both in HIV-infected patients and in subjects receiving prophylaxis after HIV-
exposure , but also with other antiretrovirals such as zalcitabine (ddC) . 
Mitochondrial toxicity 
It is infrequent but a distinctive type of hepatoxicity that may evolve to acute liver 
failure. Mitochondrial toxicity is explained in another article. The main feature of the 
hepatic lesion is the accumulation of microvesicular steatosis in liver cells and 
mitochondrial depletion. This early lesion may evolve to macrovesicular steatosis with 
focal necrosis, fibrosis, cholestasis, proliferation of biliary ducts, and Mallory bodies, a 
clinical picture resembling alcohol-induced liver toxicity, pregnancy steatosis or Reye's 
syndrome . Of interest, the underlying liver disease does not predispose to this type of 
 28
lesion . The ability of NRTI to inhibit mitochondrial DNA synthesis in vitro is in the 
following order: ddC, ddI, d4T, AZT, 3TC=ABC=TDF . Hydroxyurea, used as 
coadjuvant treatment with ddI to enhance its activity, seems to increase the toxic effect 
of some NRTI. 
Metabolic abnormalities 
Steatohepatitis may cause hypertransaminasemia. Insulin resistance is believed to be the 
metabolic hallmark of predisposition to non-alcoholic steatohepatitis (NASH). HAART 
may cause, in the context of the lipodystrophy syndrome, marked abnormalities in the 
metabolism of both lipids and glucose, including insulin resistance . Mild-to-moderate 
degrees of steatosis have been found in the liver of patients experiencing HAART-
derived hepatotoxicity . Thus, in some patients receiving HAART, insulin resistance and 
NASH may contribute to the development of liver toxicity. 18 
Studies in HIV-negative individuals find rosiglitazone and pioglitazone can reduce risks 
associated with metabolic syndrome and can reduce risks for cardiovascular disease 
associated with insulin resistance and diabetes, as well as in non-diabetics. Preclinical 
studies suggest that atazanavir may reduce risk for glucose anmormalities in HIV+ 
patients who have not yet developed glucose abnormalities compared to other PIs 
associated with risk for glucose abnormalities.  
Immune reconstitution in HCV and/or HBV-infected patients 
Liver damage induced by chronic HCV and HBV infection is mainly immune-mediated. 
The immune deficit caused by HIV infection is responsible for the attenuation of the 
inflammatory reaction in the liver of co-infected subjects. The inhibition of HIV 
replication with HAART leads to immune reconstitution, and consequently the immune 
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response to HCV and/or HBV antigens exposed in the liver cell is also restored. Thus, 
HAART therapy may induce the development of hypertransaminasemia and even 
symptomatic hepatitis in patients with HCV or HBV co-infection. 
The immune reconstitution syndrome as a mechanism of liver toxicity is controversial, 
but there are several data supporting it. Markers of HCV-specific immune responses 
(HCV core-specific IGG antibody), T-cell activation and inflammation, have been found 
to correlate with liver damage and immune reconstitution. Some authors have identified 
an increase in >50 CD4 cells per mm3 after initiating HAART as an independent risk 
factor for hepatotoxicity . Liver histology has shown exacerbated viral hepatitis in some 
patients developing severe hypertransaminasemia while on HAART . 
 
FIG. 2.1 : MECHANISMS OF HEPATOTOXICATY 
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THERAPEUTIC MANAGEMENT 
The three main considerations necessary for the management of transaminase elevation 
after the introduction of HAART are severity, clinical impact and etiologic mechanisms. 
Suspicion of hypersensitivity reactions or lactic acidosis, and the presence of liver 
decompensation, are all reasons to stop treatment]. Severe liver toxicity (grades 3-4), 
even in the absence of symptoms warrants discontinuation of the antiretroviral therapy. 
  
In the remaining cases, decisions should be made on an individual basis. If liver steatosis 
is present, it is indicated to pursue the removal of predisposing factors. If the patient is 
taking an antiretroviral with higher hepatotoxic potential, substitution of that particular 
drug is an available option. Regarding the continuation of the same regimen, 
spontaneous decrease of transaminases levels has been reported . However, the elevation 
of transaminases can persist, and the long-term consequences are unknown. In that 
regard, the finding of an association between NVP use and hepatic fibrosis is worrisome. 
Nevertheless, this is a single study, and its results should be confirmed by other 
investigations.  
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FIG 2.2 :  THERAPEUTIC ALGORITHM 
 
Management 
Management of HAART-related hepatotoxicity is complicated by the desire of the 
practitioner to minimize adverse effects while  at the same time relying on the chronic 
use of potentially hepatotoxic agents to prevent life threatening complications from 
immunodeficiency.  Early withdrawal of therapy is recommended for patients who 
develop symptomatic or severe hyperlactatemia because of a nearly linear association 
between serum lactate values and mortality. There are anecdotal reports of the use of 
antioxidants such as riboflavin, L-carnitine, and coenzyme Q-10 (ubiquinone).  No 
controlled studies are available to evaluate these reports.  After serum lactate levels and 
LFTs normalize, reinitiation of retroviral therapy without NRTIs or utilizing NRTIs 
which have a lower likelihood of causing lactic acidosis, such as lamivudine, abacavir, 
and tenofovir.18 
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ASSESSMENT OF LACTIC ACIDOSIS IN PATIENTS WITH HIV 
Table 2.4 : Signs and symptoms 
 
 
Nausea 
Vomiting 
Weakness 
Abdominal pain 
Diarrhea 
 
 
Malaise 
Anorexia 
Dyspnea 
Cardiac arrhythmia (fatal) 
 
 
Table 2.5 : Management 
 
Discontinue ART  
Deliver adequate oxygen to tissues 
Reduce O2 demand  
Mechanical ventilation 
 
 
Liver biopsy plays an important role in distinguishing between the above mentioned 
types of HAART-associated hepatotoxicity.  By laboratory criteria, most patients with 
Grade 0, 1, or 2 hepatotoxicity are observed closely, as the benefit of continuing an 
effective antiretroviral regimen outweighs the risk of severe hepatotoxicity.  Patients 
with Grade 3 or 4 hepatotoxicity or cholestasis are advised to discontinue therapy.  
Treatment can be re-initiated with a different class of drugs when LFTs have normalized. 
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3. AIM OF THE STUDY 
 
 
 
 
The study was conducted with the objective of 
 
i. estimate the incidence of drug induced hepatotoxicity in patient receiving 
HAART therapy for HIV/AIDS 
ii. to analyze the risk factors that are associated with drug induced 
hepatotoxicity in these patients and their clinical profile. 
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4. MATERIALS & METHODS 
About 1523 patients who receive ART were screened and patients with evidence of liver 
dysfunction were isolated. Sample population was selected as follows. 
50 adult patients of both sexes infected with HIV and fulfill the WHO criteria for clinical 
AIDS receiving HAART for a period of more than 1 month were included in the study.  
PATIENT SELECTION 
Inclusive criteria  
Patients with HIV infection  
i. who receive HAART therapy for > 1 month 
Exclusion criteria 
i. Patients with base line LFT abnormal 
ii. No evidence of extrahepatic cause of jaundice 
iii.  No past history of jaundice 
iv. No clinical evidence of liver disease at the institution of HAART 
v. Antenatal mothers 
vi. Children < 13 years  
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PROTOCOL 
1.    All patients who receive HAART therapy who met the above criteria were included 
in the study 
2.    The following were noted in each patient 
i. Age 
ii. Sex 
iii. BMI 
iv. Alcohol usage 
v. Smoking 
vi. H/o jaundice in the past 
vii. Drug allergy 
viii. Diabetes 
ix. Tuberculosis (pulmonary/ extra pulmonary) 
x. Mode of acquisition of HIV 
xi. Nadir CD4 count 
xii. Latest CD4 count 
xiii. Socio economic status 
xiv. Dose of each drug 
xv. Duration of therapy of each drug 
xvi. Drug withdrawal 
xvii. Other adverse reaction with the drug 
xviii. Anti tubercular therapy (ATT) 
xix. Anti fungals 
xx. Antibiotics 
 36
3.    Base line LFTs were measured  
4.   Those who have abnormal LFT following were noted 
i. USG 
ii. HBsAg, anti HCV antibodies 
iii. Prothrombin time 
iv. Chest X ray 
v. Complete blood count 
vi. Bleeding time 
THE STUDY 
Study design        Retrospective  Analytical Study 
Venue          GGH, Chennai 
Duration         6 months 
Collaborating departments 
ART Clinic, Govt. General Hospital, Chennai 
ART Clinic, Govt. Hospital for Thoracic Medicine, Tambaram 
ART Clinic, Kilpauk Medical College Hospital, Chennai 
Liver Clinic, Govt. General Hospital, Chennai 
 
STASTICAL ANALYSIS 
 
Statistical analysis were made by Oneway ANOVA F test. Difference between variables 
calculated by Chi- Squared test and Student independent t- test using SSPS software. 
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RISK FACTORS FOR HEPATOTOXICITY IN PATIENTS ON 
HAART 
 
 
      PROFOMA 
 
S.NO. 
 
NAME                      AGE  SEX                           UNIT 
    
 
OCCUPATION    
 
ADDRESS  
 
CONTACT NO. 
 
HOSPITAL NO                                      
 
 
SYMPTOMS  
 
PRIMARY SYMPTOMS 
 
GI SYMPTOMS 
 
Fever 
 
Jaundice 
 
Loss of appetite 
 
Loss of weight 
 
Pruritus 
 
GI bleed  
 
PAST HISTORY 
 
Jaundice 
 
Abdominal surgery 
 
Blood transfusions 
 
Hepatotoxic drug intake 
 
Alcohol  
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Smoking  
 
Tobacco usage of other means 
 
IVDU 
 
Drug abuse 
 
Marital status 
 
Promiscuity     M2F / M2M 
  
 
SIGNS 
 
General  
 
Weight                       height  
 
Nutrition                     BMI 
 
Pallor 
 
Oral lesions 
 
Jaundice 
 
Evidence of liver cell failure 
 
Ascites 
 
Cutaneous bleed 
 
Hepatic encephalopathy 
 
 
DURATION OF HAART 
 
NO OF DRUGS  DOSE 
  
Drugs Started on Stopped on Dose 
     
    
    
   
 39
 
ATT     
 
Drugs Dosage Duration Comments 
    
    
    
 
 
OTHER ANTIVIRALS  ANTIFUNGAL 
 
 
ANTIBIOTICS 
 
 
OTHER DRUGS 
 
     
CAM 
 
 
PAST H/O JAUNDICE 
 
 
ALCOHOL     Y/N   DETAILS   SMOKING 
 
 
IV DRUG ABUSE 
 
 
NUTRITIONAL STUATUS    BMI 
 
 
PRETREATMENT LFT   SERIAL LFT         
 
 
HBsAg     Anti HCV 
 
 
CMV      HSV                                                  DM 
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5. RESULTS 
 
Baseline data 
 
Total screened    :  1253 
 
Sample size :  50           hepatotoxicity  :  3.9% 
 
Males  : 35                    Females  : 15 
 
Age  :  17 to 49 years           Mean age   : 31 
 
BMI  : 16 - 30                      Mean    : 21.2 
 
CD4 count    : 10 - 185               Mean    : 122.5 
 
 
LFT 
 
Pretreatment LFT  Post treatment LFT 
Range Mean  Range Mean 
0.7-1.1 0.9 T.BIL 0.9-24.5  
  D.BIL 0.8-20.4  
15 – 42 25.6 AST 77 – 1048 280.1 
15 – 43 27.4 ALT 88 – 1138 342 
  PT 0 – 10 1.4 
 
 
HBV co-infection  : 10   (20%)  M : F  8:2 
 
HCV co-infection:   2    (4%)   
 
Alcohol abuse:  16 
 
 
Baseline date were analyzed by ANOVA F test and found to have no difference between 
the variables in all the groups. The samples were well matched.( Table 5.1, 5. 2) 
 41
Table 5.1  
 
REGIMEN 
Oneway ANOVA F_test
ALN SLN SLE 
Mean SD Mean SD Mean SD 
Age 30.86 7.58 31.95 9.22 26.22 7.01 F=1.55   P=0.22 
BMI 21.23 2.88 20.00 3.32 21.89 4.43 F=1.17   P=0.31 
CD4nadir 122.45 28.36 99.00 33.81 92.22 61.93 F=2.89   P=0.07 
duration 6.64 4.04 5.21 3.54 3.78 1.64 F=2.24   P=0.11 
bilirubin 1.26 1.51 .92 .12 .91 .15 F=0.71   P=0.49 
AST 25.64 7.05 25.42 7.43 27.11 7.20 F=0.18   P=0.83 
ALT 27.45 7.93 28.32 4.03 30.89 5.21 F=0.97   P=0.39 
ALP 130.05 26.69 133.58 29.40 130.22 30.82 F=0.09   P=0.91 
Albumin 3.07 .21 3.11 .22 3.17 .28 F=0.55   P=0.58 
 
 
Considering associations between various treatment regimens  
REGIMEN 1 : Zidovudine + Lamivudine + Nevirapine (ALN)  
REGIMEN 2 : Stavudine + Lamivudine + Nevirapine (SLN)  
REGIMEN 3: Stavudine + Lamivudine + Efavirenz (SLE) and  
Liver Function Test (TB,AST,ALT,ALP,PT). 
The data were analysed by One way ANOVA F test. There was no statistical difference 
between different regimens in causing hepatitoxiciy (p> 0.05). 
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Table 5.2  
 
 
REGIMEN 
Oneway ANOVA F_test
ALN SLN SLE 
Mean SD Mean SD Mean SD 
T_BIL 2.93 1.53 5.88 5.73 3.90 4.52 F=2.62   P=0.08 
AST1 234.27 153.14 350.00 296.04 286.00 265.46 F=1.21   P=0.30 
ALT1 318.68 184.87 416.79 334.13 292.44 247.54 F=0.99   P=0.38 
ALP1 196.59 49.90 242.95 160.40 186.22 86.59 F=1.21   P=0.30 
PT_N 1.36 1.84 1.89 2.31 1.11 1.27 F=0.62   P=0.55 
 
 
Considering Age as an independent factor for elevated liver enzymes, 3 age groups were 
analysed ( A < 30 yrs, B 31- 40, C >40). There was no ststistical significance  between 
age and Bilurubin level, AST, ALT, ALP and Prothrombin time (PT). p 0.22 
 
BODY MASS INDEX (BMI) 
Analysis of data with BMI as an independent variable showed strong correlation with 
elevation of Total Bilirubin, AST, ALT, ALP and PT (p<0.05) 
Table 5.3  
 
 BMI(<18.5) BMI(>18.5) Student Independent 
t-test  Mean SD Mean SD 
T_BIL 5.93 6.77 3.43 2.05 t=3.95 P=0.05 significant 
AST1 377.38 329.75 245.29 169.62 t=3.53 P=0.04  significant 
ALT1 489.00 344.01 286.41 185.20 t=7.37 P=0.007 significant 
ALP1 243.13 167.68 197.85 69.79 t=1.83 P=0.18 notsignificant 
PT_N 1.63 2.58 1.47 1.60 t=0.07 P=0.03 significant 
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SEX 
Comparing the means of liver function tests with Sex did not show statistically 
significant correlation (p =0.13) (Table A.) 
 
CD4 Count 
The association of hepatotoxicity with different CD4 counts catagories was analyzed. 
Patients belonging to CD4 count < 100 have significant correlation with TB, AST, ALT, 
and PT. (p 0.04). The risk of hepatotoxicity correlates well with low CD4 count whereas 
in groups with CD4 count between 100-150 and > 150 did not show any correlation. 
 
Table 5.4 
 
 CD4nadir 
Oneway ANOVA 
F_test 
  <100 101-150 >150 
  Mean SD Mean SD Mean SD 
T_BIL 6.12 6.02 3.23 2.33 2.49 0.79 F=3.40   P=0.04 significant 
AST1 383.89 306.57 242.17 179.88 181.71 70.87 F=3.12   P=0.05 significant 
ALT1 420.00 336.85 311.83 194.66 299.71 221.30 F=1.07   P=0.35 Not significant 
ALP1 241.00 155.71 199.63 71.35 178.14 62.77 F=1.12   P=0.03  significant 
PT_N 1.89 2.33 1.50 1.79 .57 .79 F=1.21   P=0.01  significant 
 
 
ALCOHOL 
 
Correlation with alcohol and hepatoxicity did not show any statistical significance.  
(p =0.53).The risk of hepatotoxicity did not have correlation with alcohol consumption. 
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HEPATITIS B 
Coinfection with HBV increases the risk of hepatotoxicity.The data analyzed show 
positive correlation with HBV positivity  with TB, AST, ALT, PT (p0.001). Patients 
with HBV infection had higher levels of T.B, AST, ALT and Prothrombin compared to 
negative group.  
 
On combining HBV coinfection and alcohol abuse there was a positive correlarion with 
TB, AST, ALT, PT. (p < 0.03). (Table 5.4) 
Table 5.4 
  
 HBV 
Student Independent 
t-test 
  No Yes 
  Mean SD Mean SD 
T_BIL 3.80 4.50 5.92 2.73 t=1.89 P=0.04 significant 
AST1 229.83 203.43 518.50 233.25 t=3.90 P=0.001  significant 
ALT1 301.38 239.93 550.70 260.58 t=2.89 P=0.006 significant 
ALP1 202.30 114.86 252.50 88.23 t=1.29 P=0.22 not significant 
PT_N 1.13 1.79 3.10 1.79 t=3.12 P=0.002 significant 
 
 
 
 
 
. 
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6. DISCUSSION 
 
There is an increase in the reporting of drug induced liver injury following ART therapy 
since 1995 following wide spread usage of antiretrovirals.12 
 
The incidence of drug hepatotoxicity has been variously reported. It ranged from 5% to 
30% in different series (17 cohorts and 2 metanalyses). Less often they cause steatosis, 
Lactic acidosis and encephalopathy with mortality rates between 0.1 to 7% 
 
Our incidence is likely to be around 3.9%when grade 3 or 4 injury is taken as cut off 
limit. 
 
We compared our results with that of the literature available on this issue. Much of the 
data came from large trials like Amsterdam, CHORUS, ICONA and TARGET which 
involved more than 5100 patients.3,4,14,15,16,17 
 
AGE, SEX AND BMI 
 
Age was not considered to be an individual risk factor in most of the published series. 
Large trials like Saves17 failed to demonstrate any correlation with age. Our series also 
found no correlation to the incidence of hepatotoxicity with age. 
 
Female sex was associated with increased incidence of hepatotoxicity in two of the major 
trials. Martin-Carbonero23 et al and Wit et al16 have shown independently that female sex 
is an independent risk factor and the risk increases with females who are obese and who 
drink alcohol. Our data found no correlation of hepatotoxicity with gender. Both sexes 
had equal incidence of liver injury. However the only mortality in our series happened in 
a female patient. 
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Obese patients had a higher risk of hepatic steatosis and liver injury (Carr A et al). Other 
studies have shown that malnutrition and low BMI are also contributory factors in 
hepatic injury in Asian and African populations (Sampras K et al). In our series there is a 
strong correlation with liver injury (Bilirubin level, AST, ALT ) with low BMI (< 18.5), 
but did not have impact on normal BMI. Our study population did not include obese 
BMI patients and thus could not be compared. 
 
DRUGS AND REGIMENS 
 
Previously number of reports of increased liver injury were attributed to certain drugs 
like Zidovudine, Nevirapine , full dose Ritonavir. Review of  17 clinical trials between 
1991 to 2001 in FDA database attributes risk of liver injury for Nevirapine (NVP) and 
Efavirenz (EFZ). In 2NN study, post exposure prophylaxis of NVP was associated with 
severe liver injury and it was recommended to exclude NVP from PEP programs. 
 
Our series included 3 standard regimen (AZT + Lamivudine + Nevirapine , Stavudine + 
Lamivudine + Nevirapine, Stavudine + Lamivudine + Efavirenz). When these were 
compared with the incidence of liver injury there was no correlation. All regimens had 
equal incidence of hepatotoxicity following therapy.20,25 
 
ALCOHOL 
Alcohol usage did not predispose to severe liver injury in studies by Saves et al,17 
Suikowski et al13 and Rodriguez-Rosado.12 However Nunez et al14 found alcohol has 
correlation particularly following PI based regimens and in obese females (Martin – 
Carbonero). Our study did not find any correlation of hepatotoxicity with alcohol usage. 
However we found that there were significant risk associated with presence of combined 
factors of alcohol and HBV 
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fig 6.1:Alcohol+ HBV Coinfection 
 
 
HEPATITIS B AND HEPATITIS C 
 
There are atleast 10 studies which show consistent association of liver toxicity with HBV 
infection. Studies by Saves, Sulkowski13, Den Brinker, D’Armino, Aceti26, Wit16, De 
Maat have shown that HBV is an individual risk factor. 
 
 The risk increased with high viral load, HBeAg positivity and raised baseline AST and 
ALT. Co infection with HCV is also identified as a contributing factor in these studies. 
Withdrawal of Lamivudine in HBV positive patients also found to have higher incidence 
of hepatotoxicity. 
 
In our patients HBV is strongly associated with increased incidence of hepatotoxicity. It 
has good correlation with Bilirubin, AST, ALT, and Prothrombin time. The incidence of 
HBV coinfection in the sample is 20% and HCV is 4%. 
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fig 6.2:HBV Co-infection 
 
CD4 COUNT  
 
The correlation with CD4 count and hepatotoxicity was found in our study. Patients with 
CD4 < 100 cells ran a higher risk of hepatotoxicity and death. This is attributed to 
profound state of immune suppression and loss of liver regeneration functions. Studies 
by Saves had similar results. 
 
A study by Sulkowski 13showed that a rise in CD4 count following HAART predisposes 
to severe hepatic injury. He attributes this phenomenon to immune reconstitution 
syndrome where restoration of cell mediated immunity caused aggressive 
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hypersensitivity reaction to drugs. This phenomenon was also confirmed by other recent 
studies.15,16,17 
 
Most of our patients had  CD4 counts  moderately elevated after induction of ART and 
this phenomenon was not observed in our series.  
 
CONSTITUTIONAL SYMPTOMS 
 
We found the presence of rash in about 13.5% of cases preceding liver injury. Fever, 
malaise, nausea, myalgia and arthralgia occurred in about 33.3%. The incidence was 
more with Stavudine, Lamivudine and Nevirapine regimen. This observation was not 
noted in other published series so far. 
 
Presence of peripheral eosinophilia is observed in 13.5% which was lower than observed 
in Wit et all where he reports it to be around 28% 
 
Presence of rash was neither sensitive nor specific in diagnosing drug induced liver 
disease following HAART therapy. (fig A 1) 
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7. CONCLUSIONS 
 
The following were concluded at the end of the study 
1.  Drug induced liver injury occurs in  3.9% of patients following HAART therapy 
2.  The risk factors for hepatotoxicity identified were Low BMI, Low CD4 count,     
HBV co-infection, and combined HBV  co-infection & alcohol usage. 
3.  Age, Sex, alcohol usage alone, various regimens did not have any correlation 
with the incidence and severity of hepatotoxicity. 
4. The occurrence of rash or constitutional symptoms had poor sensitivity and 
specificity for drug induced hepatotoxicity in these patients. 
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8. SUMMARY 
 
The study was initiated with the primary aim of finding out the clinical profile and risk 
factors for the hepatotoxicity in patients receiving HAART therapy for AIDS. 
 
A total of 1523 patients were screened and patients who developed liver injury during 
ART therapy were selected. About 50 adult patients of both the sexes were included in 
the study. Records of these patients were analyzed. Further testing was done as needed.  
 
Various parameters were noted.  
 
Statistical analysis was done by Oneway ANOVA F test, Chi-squared test and Student 
independent t test, in which correlation between various parameters and hepatotoxicity 
were analyzed. 
 
Results were tabulated and compared with various published series worldwide. 
 
According to our series, the major risk factors for hepatotoxicity were Hepatitis B 
infection, Low CD4 counts, Low BMI, alcohol abuse in HBV positive patients. 
 
The risk of liver injury was independent of age, sex, various drug combinations. 
 
Clinically, rash and constitutional symptoms occur in less than one quarter of these 
patients and carry poor sensitivity or specificity. 
 
These results were comparable with publishes series from various countries although 
subtle differences exist 
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9. APPENDICES 
Graph A1: CD 4 counts and Hepatotoxicity 
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Graph A2 : Duration & Hepatotoxicity 
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Graph A3 : Liver enzymes values 
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Graph A4 : Bilirubin Values 
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Graph A5: Bilirubin & Prothrombin time 
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Fig. A1 
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Table A1 : Base line data 
 
 
REGIMEN 
Oneway ANOVA F_test
ALN SLN SLE 
Mean SD Mean SD Mean SD 
age 30.86 7.58 31.95 9.22 26.22 7.01 F=1.55   P=0.22
BMI 21.23 2.88 20.00 3.32 21.89 4.43 F=1.17   P=0.31
CD4nadir 122.45 28.36 99.00 33.81 92.22 61.93 F=2.89   P=0.07
duration 6.64 4.04 5.21 3.54 3.78 1.64 F=2.24   P=0.11
bilirubin 1.26 1.51 .92 .12 .91 .15 F=0.71   P=0.49
AST 25.64 7.05 25.42 7.43 27.11 7.20 F=0.18   P=0.83
ALT 27.45 7.93 28.32 4.03 30.89 5.21 F=0.97   P=0.39
ALP 130.05 26.69 133.58 29.40 130.22 30.82 F=0.09   P=0.91
Albumin 3.07 .21 3.11 .22 3.17 .28 F=0.55   P=0.58
 
 
 
Table A2 : Baseline Data 
 
 
REGIMEN 
Chi-squared test 
ALN SLN SLE 
n  % n  % n  % 
Sex Male 16 72.7% 14 73.7% 5 55.6% χ2=1.09  
P=0.59 Female 6 27.3% 5 26.3% 4 44.4%
alcohol No 15 68.2% 10 52.6% 8 88.9% χ2=3.66 
P=0.16 Yes 7 31.8% 9 47.4% 1 11.1%
HBV No 17 77.3% 15 78.9% 8 88.9% χ2=0.56 
P=0.76 Yes 5 22.7% 4 21.1% 1 11.1%
 
HCV 
No 21 95.5% 18 94.7% 9 100.0% χ2=0.47 
P=0.79   Yes 1 4.5% 1 5.3%     
 
 
Table A3 : Constitutional Symptoms 
 
 REGIMEN 
Chi-squared 
test 
  ALN SLN SLE 
  Count % Count % Count % 
RASH No 19 86.4% 16 84.2% 8 88.9% χ2=0.11
P=0.94  Yes 3 13.6% 3 15.8% 1 11.1% 
EOSINOPHILIA No 19 86.4% 16 84.2% 8 88.9% χ2=0.11
P=0.94  Yes 3 13.6% 3 15.8% 1 11.1% 
CONST.S1 No 19 86.4% 9 47.4% 6 66.7% χ2=7.13
P=0.03
significant
  Yes 3 13.6% 10 52.6% 3 33.3% 
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Table A4 :  Age 
 
 Age 
Oneway ANOVA 
F_test 
  <30 31-40 >40 
  Mean SD Mean SD Mean SD 
T_BIL 3.74 3.59 4.07 2.86 6.41 8.17 F=1.10   P=0.34
AST1 279.12 214.21 259.29 197.15 387.57 390.70 F=0.75   P=0.49
ALT1 351.23 245.96 291.94 201.24 495.29 405.80 F=1.53   P=0.22
ALP1 189.35 62.09 222.12 89.08 274.00 237.86 F=1.75   P=0.18
PT_N 1.58 1.81 1.12 1.17 2.29 3.50 F=0.92   P=0.41
 
 
Table A5 : BMI 
 
 BMI(<18.5) BMI(>18.5) Student Independent  
t-test   Mean SD Mean SD 
T_BIL 5.93 6.77 3.43 2.05 t=3.95 P=0.05 significant
AST1 377.38 329.75 245.29 169.62 t=3.53 P=0.07 Not significant
ALT1 489.00 344.01 286.41 185.20 t=7.37 P=0.007 significant
ALP1 243.13 167.68 197.85 69.79 t=1.83 P=0.18 notsignificant
PT_N 1.63 2.58 1.47 1.60 t=0.07 P=0.96 Notsignificant
 
Table A6 : Sex 
 
 Sex
Student Independent  
t-test 
  Male Female 
  Mean SD Mean SD 
T_BIL 4.82 4.91 2.84 1.56 t=1.52 P=0.13 notsignificant
AST1 320.74 259.00 210.13 160.60 t=1.53 P=0.13 Not significant
ALT1 385.03 290.15 272.40 159.90 t=1.41 P=0.16 notsignificant
ALP1 220.31 123.36 193.73 75.56 t=0.77 P=0.44 notsignificant
PT_N 1.71 2.11 1.07 1.44 T=1.08 P=0.24 Notsignificant
 
Table A7 : Alcohol 
 
 Alcohol 
Student Independent  
t-test 
  No Yes 
  Mean SD Mean SD 
T_BIL 4.43 5.09 3.82 1.93 t=0.47 P=0.64 notsignificant 
AST1 288.91 250.33 284.94 218.64 t=0.05 P=0.96 Not significant 
ALT1 334.52 270.51 383.71 248.09 t=0.63 P=0.53 notsignificant 
ALP1 214.85 122.31 207.47 88.55 t=0.22 P=0.83 notsignificant 
PT_N 1.58 2.24 1.41 1.23 t=0.28 P=0.78 Notsignificant 
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